T-DXd significantly extends progression-free survival in HER2-mutant NSCLC

First-line treatment with trastuzumab deruxtecan (T-DXd) significantly improved progression-free survival compared with pembrolizumab plus platinum-based chemotherapy in patients with advanced or metastatic HER2-mutant non-small cell lung cancer (NSCLC), according to…

Continue ReadingT-DXd significantly extends progression-free survival in HER2-mutant NSCLC

Like your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link

In pooled prospective data from 977,282 UK adults, preferring tea or coffee “very hot” was associated with more than threefold higher risk of esophageal squamous cell carcinoma compared with preferring…

Continue ReadingLike your tea or coffee very hot? A study of nearly 1 million adults found a striking cancer link